|
Mammary Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In addition, BIRC5 expression may induce breast tumor proliferation by promoting genetic instability.
|
18181175 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additionally, plasmid-based siRNA against Birc5 and/or Hspa5 were constructed and transfected into the human hepatocellular liver carcinoma cell line, HepG2.
|
22581315 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Besides, genes BIRC5, CDC20, CCNB1, BUB1B, MAD2L1 and CDK1 as the hub genes might play important roles for diagnosing and therapy of HCC.
|
25753876 |
2015 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we deeply mined the integrated large-scale datasets from public microarrays and immunohistochemistry to validate the overexpression of BIRC5 and SQSTM1 while down-regulated FOXO1 expression in HCC.
|
29707114 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared the same and different activated and inhibited BIRC5 network with GO analysis between no-tumor hepatitis/cirrhosis and HCC, our result showed BIRC5 cell cycle network weaker transcription factor activity in both no-tumor hepatitis/cirrhosis and HCC (1); stronger nucleus protein binding but weaker cytoplasm protein binding in no-tumor hepatitis/cirrhosis (2); stronger cytoplasm protein phosphatase binding but weaker ubiquitin-protein ligase activity in HCC (3).
|
21312234 |
2011 |
|
Squamous cell carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
To investigate, whether increased copy numbers of the survivin-encoding gene BIRC5 results in elevated survivin levels and whether BIRC5 and survivin could serve as progression markers in the clinical course of OSCC, tumor tissue microarray analysis was performed applying fluorescence in situ hybridization and immunohistochemistry to 296 OSCC specimens.
|
17187360 |
2007 |
|
Squamous cell carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Integrative Histologic and Bioinformatics Analysis of BIRC5/Survivin Expression in Oral Squamous Cell Carcinoma.
|
30205554 |
2018 |
|
Squamous cell carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Specifically, we found that BIRC5, which codes for survivin, is upregulated in both adenocarcinoma and squamous cell carcinoma tissues and that high expression of BIRC5 is associated with poor survival in adenocarcinoma, but not squamous cell carcinoma.
|
29416000 |
2018 |
|
Squamous cell carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the potential expression and prognostic significance of the apoptosis inhibitor survivin in squamous cell carcinoma (SCC).
|
11418003 |
2001 |
|
Colorectal Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Serum cell free BIRC5 mRNA is a promising non-invasive biomarker for diagnosis and prognosis of CRC.
|
24338523 |
2014 |
|
Colorectal Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
|
26277021 |
2015 |
|
Colorectal Carcinoma
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Infection with pAd-T34A caused spontaneous apoptosis in cell lines of breast, cervical, prostate, lung, and colorectal cancer.
|
11581299 |
2001 |
|
Colorectal Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
This review summarizes the current knowledge about the splice isoforms of VEGFA, UGT1A, PXR, cyclin D1, BIRC5 (survivin), DPD, K-RAS, SOX9, SLC39A14 and other genes, which may be possible therapeutic targets for colorectal cancer.
|
23118106 |
2012 |
|
Colorectal Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Further studies are warranted on the apoptotic mechanisms linked to the reciprocal regulation of BMF and BIRC5 in human colorectal cancers characterized by Eomes overexpression.
|
27539959 |
2016 |
|
Colorectal Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
Survivin/BIRC5 is a potentially interesting prognostic marker and therapeutic target in colorectal cancer (CRC).
|
23755220 |
2013 |
|
Colorectal Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
The results showed VEGF (71.4%), SOX9 (68.8%), MYC (62.3%), CCND1 (59.7%), TP53 (59.4%), MMP9 (53.3%), and BIRC5 (50.6%) as significantly overexpressed genes in CRC tissues.
|
24240588 |
2013 |
|
Colorectal Carcinoma
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
DR5, BIRC5/Survivin, XIAP, c-IAP1 and c-IAP2 mRNA expression are significantly deregulated in CRC and could provide a panel of markers with significant discriminatory value between CRC and normal colorectal tissue.
|
27827395 |
2016 |
|
Colorectal Carcinoma
|
0.390 |
Biomarker
|
disease |
BEFREE |
In conclusion, we demonstrated that high miR-218 expression had a positive prognostic value in 5-FU-based treatments for CRC patients and discovered a novel mechanism mediated by miR-218 to promote apoptosis and to function synergistically with 5-FU to promote chemosensitivity by suppressing BIRC5 and TS in CRC.
|
26442524 |
2015 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, BIRC5, CENPA and FAM64A are specifically upregulated in TNBC, and the high expression of these three genes is associated with poor breast cancer prognosis, suggesting their clinical implication as therapeutic targets in TNBC.
|
24676531 |
2014 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
The apoptosis inhibitor survivin is one of the most specific proteins in breast cancer patients.
|
17695451 |
2007 |
|
Breast Carcinoma
|
0.370 |
GeneticVariation
|
disease |
BEFREE |
Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?
|
16873289 |
2006 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
Results in previous qualitative studies of the association of the apoptosis inhibitor survivin with prognosis of breast cancer patients have been contradictory.
|
15364883 |
2004 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas.
|
18181175 |
2008 |
|
Breast Carcinoma
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Nanodrug uptake by human breast adenocarcinoma cells resulted in a significant downregulation of BIRC5.Following i.v. delivery into subcutaneous mouse models of breast cancer, the nanodrug showed a preferential tumor uptake, which could be visualized by MRI and near-IR optical imaging.
|
20702603 |
2010 |
|
Breast Carcinoma
|
0.370 |
Biomarker
|
disease |
BEFREE |
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
|
27592112 |
2016 |